Karyopharm Therapeutics Inc. (KPTI) AI Stock Summary

Snapshot

Karyopharm is a commercial-stage biotech with a healthy product gross margin (96%) but a deeply strained balance sheet. The company generates roughly $146M in revenue, yet spends heavily on R&D and sales (158% of revenue combined), leading to a $196M net loss and a $75M annual cash burn. With only $64M in cash against $234M in debt, the company has entered a forbearance agreement and disclosed a going-concern warning, explicitly stating it may not survive the next year without raising more capital. Investors have seen significant dilution, with the share count rising 35% in the last year.

What's Happening Right Now

• Thu 30th Jul '26 · Clinical trial: The Phase 3 endometrial cancer trial missed its primary endpoint, and the company plans to reduce investment in that area to prioritize myelofibrosis and multiple myeloma programs.
• Thu 30th Jul '26 · Regulatory: Karyopharm plans to submit a supplemental New Drug Application in August 2026 for accelerated approval of selinexor plus ruxolitinib in myelofibrosis.
• Thu 14th May '26 · Financial distress: The company disclosed a going-concern warning in its Q1 2026 10-Q, stating there is substantial doubt it can continue operating within one year without raising additional capital.

Ownership

Institutions hold 76.5% and insiders hold 3.7%.

Bottom Line

This is a distressed biotech betting its survival on a successful regulatory submission for its myelofibrosis drug. While the product has strong sales and the clinical data showed promise, the financial picture is critical. The going-concern warning and high debt load make this a high-risk situation where the company needs to raise capital quickly to avoid insolvency.